Nobel Biocare

Nobel Biocare is a Swiss-headquartered dental-technology company and brand whose principal business is the development and manufacture of dental implants and the restorative, digital, and clinical products used around them. Its products are intended for dental professionals treating tooth loss, including cases involving single missing teeth, multiple missing teeth, and complete-arch restoration. The portfolio extends beyond the implant fixture itself to abutments, crowns, bridges, surgical instruments, drilling equipment, biomaterials, scanning systems, computer-aided design and manufacturing solutions, diagnostic software, treatment-planning software, and patient-specific guided-surgery templates. The company’s origins lie in the work of Swedish physician and researcher Professor Per-Ingvar Brånemark, whose research established the clinical importance of osseointegration: the capacity of titanium to form a stable biological connection with bone. In 1978, Brånemark entered a partnership with the Swedish industrial group Bofors to industrialize the discovery. Bofors Nobelpharma was established in Gothenburg in 1981, initially commercializing the Brånemark System and related components. This history gave the business a strong association with evidence-based implantology and with the development of titanium implant dentistry as a repeatable clinical discipline. During the 1980s, the company expanded internationally after regulatory authorization for titanium implants in the United States. It created or developed operations in the United States, Canada, Japan, France, Spain, Australia, Italy, Germany, and the United Kingdom. It also broadened its product base. The Procera technology, developed by Matts Andersson, introduced a high-precision, automated approach to the manufacture of dental crowns and other prosthetic restorations. Nobelpharma acquired the technology in 1988, creating an early foundation for the company’s later CAD/CAM strategy. The business adopted the name Nobel Biocare in 1996. Its growth in the following years combined internal product development with acquisitions, including the purchase of American implant manufacturer Steri-Oss in 1998. In 2002, a new Swiss-domiciled group parent was established and the company’s organizational structure was reorganized around Switzerland. The company was listed on the Stockholm Stock Exchange in 1994 and later had its primary listing on the SIX Swiss Exchange; the Stockholm listing was discontinued in 2008. Nobel Biocare’s modern proposition connects surgical implant therapy with restorative and digital workflows. Its NobelProcera portfolio supports the design and production of individualized prosthetic restorations, while its scanning, diagnostic, planning, and guided-surgery tools are intended to coordinate treatment from initial assessment through implant placement and final restoration. The company also offers biomaterials and clinician training, recognizing that implant therapy depends on professional technique, case selection, and local regulatory requirements as well as on hardware. Danaher Corporation acquired Nobel Biocare in 2014, after which Nobel Biocare ceased to be separately listed. Danaher subsequently reorganized its dental businesses into Envista Holdings Corporation, a dental-products company that became an independent publicly traded company in 2019. Nobel Biocare therefore operates as an active dental brand within the Envista organization rather than as an independently listed company. Its principal identity remains that of a specialist provider of implant-based and digitally enabled restorative dentistry.

Nobel Biocare developed from Swedish research into osseointegration, the biological integration of titanium with bone. Professor Per-Ingvar Brånemark’s work demonstrated that titanium could provide a stable foundation for dental prostheses. In 1978, Swedish health authorities approved the clinical use of dental implants, and Brånemark began working with Bofors to industrialize the technology and make it available beyond the original research setting. Bofors Nobelpharma was established in Gothenburg in 1981. The company commercialized the Brånemark System and progressively added abutments, drilling equipment, instruments, and other components required for implant treatment. Brånemark presented clinical results at the 1982 Toronto Conference on Osseointegration in Clinical Dentistry. In the same period, United States authorization for titanium dental implants opened an important international market. Nobelpharma USA was established in 1983, followed by operations in Canada and Japan and additional European and Australian markets. A second important strand of the company’s history began with the Procera technology. Matts Andersson developed a high-precision, repeatable process for manufacturing dental crowns through automated CAD/CAM methods. Nobelpharma acquired the technology in 1988, helping the business move from a focus on implant fixtures toward a broader implant-and-restoration model. Swedish approval of the Procera technique followed in 1989, the year the company recorded its first profit. The Brånemark System became a registered trademark in the United States in 1990. Nobelpharma was listed on the Stockholm Stock Exchange in 1994 to support further expansion and changed its name to Nobel Biocare in 1996. In 1998, the company acquired Steri-Oss, an American implant manufacturer, strengthening its position in the North American implant market. It also established manufacturing capacity in the United States, including a plant in Mahwah, New Jersey. In 2002, the business created a Swiss-domiciled group parent and reorganized its corporate structure around Switzerland. Its primary share listing moved to the SIX Swiss Exchange, while the Stockholm listing was later discontinued in 2008. During this period, Nobel Biocare expanded its digital dentistry activities, including prosthetic design and production, scanning, clinical diagnostics, treatment planning, and guided implant surgery. Guided-surgery capabilities were introduced to the company’s offering in 2005, linking digital planning with patient-specific surgical templates. The company’s manufacturing and development footprint came to include implant production in Karlskoga, Sweden; Yorba Linda, California; and Tel Aviv, Israel, as well as prosthetic manufacturing in Mahwah and Chiba, Japan. Its commercial scope also includes biomaterials and education for clinicians, reflecting the dependence of implant treatment on surgical skills, restorative planning, and country-specific professional requirements. Danaher announced the acquisition of Nobel Biocare in 2014. Following completion, Nobel Biocare was no longer separately listed on the SIX Swiss Exchange. Danaher later announced in 2018 that it intended to separate its dental segment into a new independent public company. The separation was completed in December 2019 through Envista Holdings Corporation. Nobel Biocare continues as an active specialist dental brand within that broader dental organization.

1. 2019Dental business moves into Envista

   Danaher completed the separation of its dental segment into Envista Holdings Corporation.

   Source
2. 2014Acquisition by Danaher

   Danaher Corporation acquired Nobel Biocare.

   Source
3. 2005Guided surgery introduced

   Nobel Biocare introduced guided-surgery capabilities for implant treatment workflows.

   Source
4. 2002Swiss group parent established

   The company reorganized around a newly established Swiss-domiciled group parent.

   Source
5. 1998Steri-Oss acquired

   Nobel Biocare acquired the American dental-implant manufacturer Steri-Oss.

   Source
6. 1996Name changed to Nobel Biocare

   The company adopted the Nobel Biocare name.

   Source
7. 1994Stock exchange listing

   Nobelpharma was listed on the Stockholm Stock Exchange to support expansion.

   Source
8. 1988Procera technology acquired

   Nobelpharma acquired Matts Andersson’s automated CAD/CAM technology for high-precision dental prosthetics.

   Source
9. 1983United States commercial expansion begins

   Nobelpharma USA was established after United States authorization of titanium dental implants.

   Source
10. 1982Osseointegration results presented in Toronto

    Brånemark presented clinical results at the Toronto Conference on Osseointegration in Clinical Dentistry.

    Source
11. 1981Bofors Nobelpharma is established

    A new Gothenburg-based company was formed to commercialize Brånemark’s implant research.

    Source
12. 1978Brånemark and Bofors form an industrial partnership

    Per-Ingvar Brånemark and Bofors began collaborating to commercialize implant dentistry based on osseointegration.

    Source

A science-led, premium dental-technology specialist focused on implantology, restorative dentistry, and integrated digital workflows for dental professionals.

• Dental implant systemsDental implants

  Nobel Biocare’s implant systems are titanium-based fixtures placed in the jaw to replace the anchoring function of a natural tooth root. The portfolio includes implant designs and related components intended for different anatomical situations, treatment plans, and clinician preferences. Implants can support restorations for individual missing teeth, several missing teeth, or complete-arch rehabilitation.

• Brånemark SystemDental implant system

  The Brånemark System is the implant platform associated with the company’s historical origins in osseointegration research. It helped establish a standardized clinical and commercial approach to titanium dental implants and was supported by abutments, surgical instruments, drilling equipment, and restorative components.

• NobelProceraCAD/CAM dental prosthetics1988

  NobelProcera comprises digitally designed and manufactured prosthetic solutions, including individualized crowns, bridges, and implant-supported restorations. It derives from Procera technology, an automated high-precision manufacturing system acquired by Nobelpharma in 1988, and represents the company’s move into integrated digital restorative workflows.

• Digital planning and guided surgeryDental software and surgical planning2005

  Nobel Biocare provides digital tools for diagnosis, implant-treatment planning, and the preparation of patient-specific guided-surgery templates. These tools are intended to connect clinical assessment and prosthetic objectives with the planned position and surgical placement of implants.

• BiomaterialsDental biomaterials

  The company offers biomaterials used in implant and restorative treatment workflows. These materials complement implant fixtures and prosthetic components in procedures where clinicians require support for the surrounding hard or soft tissue environment.

• Professional educationDental training and education

  Nobel Biocare operates education and training programs for dental professionals in multiple countries. The programs address implant treatment and related clinical workflows, with availability and requirements varying according to local professional and regulatory rules.

• 2018Planned separation of Danaher’s dental segmentStrategy

  Danaher reviewed the structure of its portfolio and announced a plan to separate its dental businesses.

  What changed. Danaher announced that its dental segment would be spun off into an independent publicly traded company, later named Envista Holdings Corporation.

  Aftermath. The separation was completed in December 2019, placing Nobel Biocare within the Envista dental organization.

  Source
• 2014Danaher acquisitionM&A

  Nobel Biocare was an international dental-technology company with implant, prosthetic, and digital dentistry activities.

  What changed. Danaher Corporation acquired Nobel Biocare.

  Aftermath. Nobel Biocare became part of Danaher’s dental platform and was no longer an independently listed company.

  Source
• 2005Introduction of guided surgeryProduct launch

  Digital treatment planning was becoming an increasingly important part of implant dentistry.

  What changed. Nobel Biocare introduced guided-surgery capabilities linking digital planning with patient-specific templates for implant placement.

  Aftermath. The move broadened Nobel Biocare’s offering from implant hardware and restorations toward digitally coordinated clinical workflows.

  Source
• 2002Reorganization around a Swiss group parentStrategy

  Nobel Biocare reorganized its corporate structure as part of the development of the modern Swiss-headquartered group.

  What changed. A newly founded Swiss-domiciled group parent was established and the company’s organizational structure was changed.

  Aftermath. The reorganization established the corporate framework under which Nobel Biocare operated before its acquisition by Danaher.

  Source

• 2019Dental segment separation completed through Envista

  The planned corporate separation of Danaher’s dental segment was completed in December 2019, creating Envista Holdings Corporation as the new public dental company.

  M&A
  Source
• 2018Danaher announced the planned separation of its dental segment

  Danaher announced plans to separate its dental businesses into an independent publicly traded company, later named Envista Holdings Corporation.

  M&A
  Source
• 2014Nobel Biocare acquired by Danaher

  Danaher Corporation acquired Nobel Biocare, resulting in the company becoming part of Danaher’s dental platform and ending its status as an independently listed business.

  M&A
  Source

1. Nobel Biocare